<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461772</url>
  </required_header>
  <id_info>
    <org_study_id>CCRTCICA-CXCA</org_study_id>
    <nct_id>NCT01461772</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer</brief_title>
  <official_title>Comparison of Concurrent Chemoradiation Therapy With Weekly Cisplatin and Concurrent Chemoradiation Therapy With Weekly Carboplatin in Locally Advanced Cervical Cancer: Phase III Multicenter Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concurrent chemoradiation therapy with weekly cisplatin is the current standard treatment for
      patients with locally advanced cervical cancer. However, weekly cisplatin is related to renal
      toxicity and not convenient regimen. Recently, carboplatin has proved to be a good
      radiosensitizer and less renal toxicity. Weekly carboplatin is more convenient regimen for
      both patients and physicians. Weekly carboplatin may have similar efficacy with weekly
      cisplatin and may have more favorable toxicity profile. Therefore, the investigators aimed to
      evaluate the efficacy and safety of concurrent chemoradiation with weekly carboplatin in
      patients with locally advanced cervical cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Because of very slow rate of enrollement
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 months after completion of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Before each chemotherapy, an average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after completion of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>CCRT weekly carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoradiation therapy with weekly carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCRT weekly cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent chemoradiation therapy with weekly cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)</description>
    <arm_group_label>CCRT weekly carboplatin</arm_group_label>
    <arm_group_label>CCRT weekly cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36</description>
    <arm_group_label>CCRT weekly carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36</description>
    <arm_group_label>CCRT weekly cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated, histologically confirmed cervical cancer

          -  One of following histologic types Squamous carcinoma, adenocarcinoma, adenosquamous
             carcinoma

          -  Age: 20-75 years

          -  GOG performance status: 0-2

          -  Adequate organ function Bone marrow: WBC ≥ 3,000/mm3, ANC ≥ 1,500/mm3, Platelet ≥
             100X103/mm3, Hb ≥ 10.0 g/dl Kidney: Creatinine &lt; 1.25 × UNL, Liver : AST, ALT &lt; 3 ×
             UNL, T- bilirubin &lt; 1.5 mg/ mm3

          -  Contraception during study treatment

          -  Informed consent

        Exclusion Criteria:

          -  Previous chemotherapy or pelvic radiation therapy

          -  Hormone therapy within 4 weeks

          -  Concomitant malignancy within 5 years except cured basal cell carcinoma of skin

          -  Uncontrolled medical disease

          -  Pregnant or lactating woman

          -  Etc.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>May 27, 2017</last_update_submitted>
  <last_update_submitted_qc>May 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Joo-Hyun Nam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

